01509nas a2200193   4500008004100000245008000041210006900121260001600190300001000206490000600216520092600222653000801148653003401156653002401190653001801214653001601232100002301248856004401271       2022                        eng d00aCase Series on Teicoplanin Induced Thrombocytopenia – An Issue of Concern0 aCase Series on Teicoplanin Induced Thrombocytopenia An Issue of   cAugust 2022  a34-350 v83 a<p class="rtejustify">Teicoplanin is a glycopeptide antibiotic which inhibits peptidoglycan polymerization in gram-positive bacteria resulting in their cell death. Thrombocytopenia is a blood disorder in which platelet count falls below 100,000 cells/μl. Bleeding occurs when platelet falls below 20,000 cells/μl. In this case series, three patients with different clinical scenarios are explained who developed thrombocytopenia associated with teicoplanin administration during their course of medication. They were identified, assessed and reported for the ADR with the help of Naranjo ADR probability scale. As far as to our knowledge teicoplanin induced thrombocytopenia is not much studied and reported. In a current emerging use of higher antibiotics like teicoplanin, this is a serious life-threatening condition that has to be carefully monitored while on treatment with these types of higher antibiotics.</p>
10aADR10aDrug induced thrombocytopenia10aHaemolytic anaemia.10aNaranjo scale10aTeicoplanin1 aZS, Mohamed, Aamir  uhttp://jppcm.org/article/2022/8/2/34-35